2020 journal article
Design, synthesis, and evaluation of substrate - analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 32.
author keywords: Neglected tropical diseases; Chagas' disease; Trypanosoma cruzi; Amastigote; Trypomastigote; Isomerase; Substrate-analogue inhibitors; Competitive inhibition; Trypsin digestion LC-MS/MS
MeSH headings : 3T3 Cells; Aldose-Ketose Isomerases / antagonists & inhibitors; Aldose-Ketose Isomerases / metabolism; Animals; Binding Sites; Catalytic Domain; Drug Design; Enzyme Inhibitors / chemistry; Enzyme Inhibitors / metabolism; Enzyme Inhibitors / pharmacology; Kinetics; Mice; Molecular Dynamics Simulation; Protozoan Proteins / antagonists & inhibitors; Protozoan Proteins / metabolism; Substrate Specificity; Trypanocidal Agents / chemical synthesis; Trypanocidal Agents / metabolism; Trypanocidal Agents / pharmacology; Trypanosoma cruzi / drug effects; Trypanosoma cruzi / enzymology
TL;DR:
The study of Compound B served as a proof-of-concept so that next generation inhibitors can potentially be developed with a focus on using a prodrug group in replacement of the iodoacetamide moiety, thus representing an attractive starting point for the future treatment of Chagas' disease.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Source: Web Of Science
Added: February 8, 2021
Ribose 5-phosphate isomerase type B (RPI-B) is a key enzyme of the pentose phosphate pathway that catalyzes the isomerization of ribose 5-phosphate (R5P) and ribulose 5-phosphate (Ru5P). Trypanosoma cruzi RPI-B (TcRPI-B) appears to be a suitable drug-target mainly due to: (i) its essentiality (as previously shown in other trypanosomatids), (ii) it does not present a homologue in mammalian genomes sequenced thus far, and (iii) it participates in the production of NADPH and nucleotide/nucleic acid synthesis that are critical for parasite cell survival. In this survey, we report on the competitive inhibition of TcRPI-B by a substrate - analogue inhibitor, Compound B (Ki = 5.5 ± 0.1 μM), by the Dixon method. This compound has an iodoacetamide moiety that is susceptible to nucleophilic attack, particularly by the cysteine thiol group. Compound B was conceived to specifically target Cys-69, an important active site residue. By incubating TcRPI-B with Compound B, a trypsin digestion LC-MS/MS analysis revealed the identification of Compound B covalently bound to Cys-69. This inhibitor also exhibited notable in vitro trypanocidal activity against T. cruzi infective life-stages co-cultured in NIH-3T3 murine host cells (IC50 = 17.40 ± 1.055 μM). The study of Compound B served as a proof-of-concept so that next generation inhibitors can potentially be developed with a focus on using a prodrug group in replacement of the iodoacetamide moiety, thus representing an attractive starting point for the future treatment of Chagas' disease.